Hamburg, Germany, March 10, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced ‘Horizon’, the next phase in its multi-stage transformation initiative. Horizon advances the company’s evolution by implementing a new and focused operating model built across the three pillars of operations, science and commercial execution. This model is designed to generate above market growth and enhance operating leverage in an environment of normalized demand and increased expectations on scientific and operational performance, building on the Priority Reset in 2024 and the articulation of strategic levers for mid-term value creation in 2025.

Horizon will simplify organizational structures, reorganize Evotec’s global expertise into new, focused Centers of Excellence and align the company footprint to support more disciplined execution in high-value segments of the drug discovery and preclinical development market.

Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:

“Horizon represents the next step in Evotec’s structured transformation to position the company for sustainable, high-quality growth. Following the disciplined cost actions implemented over the past two years and the strategic priorities we set in 2025, we are now transforming our operating model. This will enable deeper integration, faster decision making and greater agility for our customers and partners. Horizon positions Evotec for stronger performance through 2027 and lays the foundation for further optimization and intelligent scaling toward 2030.”

Strategic Rationale

Horizon marks an important step to position Evotec for the next phase in the evolution of the global drug discovery and pre-clinical development market, driven by deeper scientific excellence and advances in data science, automation and AI. It represents a building phase after which the company will operate with a more disciplined cost base, a higher-value technology-driven revenue mix, improved operating margins and a platform capable of delivering sustainable and profitable growth. Operational streamlining will increase agility and responsiveness and will enable faster execution, particularly within Evotec’s drug and preclinical development (D&PD) business.

Horizon accelerates delivery on Evotec’s four strategic levers for mid-term value creation:

1. Above market growth rates at better-quality earnings
2. Commitment to operational excellence
3. Better monetization of technology and assets of Just – Evotec Biologics
4. Upside through returns on partnered asset pipeline

Implementation Plan

As part of the transformation, Evotec plans to further optimize its global footprint, reduced from 19 to 14 sites between 2024 and 2025, to 10 sites over the next two years. The footprint optimization will be accompanied by a workforce adjustment affecting up to 800 positions across all locations. Centers of Excellence will enable a centralized innovation infrastructure by concentrating key areas of expertise. This focused model is designed to strengthen scientific depth, enhance cross-disciplinary collaboration and support growth in high-value therapeutic and technology-driven areas.

Implementation of these measures has been initiated, with first operational effects anticipated in the second half of 2026. Horizon is expected to be substantially implemented by the end of 2027, taking into account phased workforce adjustments in accordance with local legal requirements. The organizational changes and associated charges that Evotec expects to incur are subject to a number of assumptions, including local legal requirements. The company is committed to a transparent process and does not expect material disruption to ongoing customer programs.

Paul Hitchin, Chief Financial Officer of Evotec, said:

“From a financial perspective, Horizon represents a fundamental realignment of our operating model and cost structure. We are simplifying our cost base, reallocating resources toward higher-value, intellectual property-driven programs and improving operating leverage across the business to create value for our stakeholders. While 2026 will be a transition year, our objective is a structurally more focused organization with enhanced long-term profitability and strengthened cash generation through 2027 and beyond.”

Financial Framework and Medium-Term Outlook

Considering the start of Horizon and the transition year expected in 2026, Evotec is revising its medium-term financial framework to reflect a phased trajectory from 2026 through 2030.

The revised framework incorporates the timing of restructuring measures and the continued development of the revenue mix across Evotec’s two business segments.

Preliminary FY 2025 Performance (Unaudited)

To provide transparency as part of the updated framework, Evotec is sharing preliminary, unaudited full-year 2025 financial figures, subject to completion of year-end closing and audit procedures.

For full-year 2025, Evotec expects results to fall within its previously communicated guidance ranges:

• Group revenues of approximately €788 million at the high end of the €760-800 million guidance (€811 million at constant exchange rates (CER))
• Adjusted Group EBITDA of approximately €41 million versus guidance of €30-50 million
  (€52 million CER)

Evotec will report final fourth quarter and full-year 2025 results on April 8, 2026.

Discovery & Preclinical Development (D&PD)

Preliminary unaudited revenues for the D&PD segment are expected to amount to approximately €529 million (€540 million CER), representing a year-on-year decrease of 13 %. Adjusted EBITDA for the segment is expected to amount to approximately -€12 million (-€5 million CER).

Just – Evotec Biologics (JEB)

Preliminary unaudited revenues for the JEB segment are expected to amount to approximately €259 million (€271 million CER), representing a year-on-year increase of 40 %. Adjusted EBITDA contribution from JEB is expected to amount to approximately €53 million (€57 million CER).

Horizon Financial Impact and 2026 Guidance

Horizon is expected to be substantially completed by the end of 2027. 2026 will represent a transition year, with meaningful operational improvements anticipated to become increasingly visible in the second half.

Evotec expects total run-rate cost savings of approximately €75 million from the structural Horizon measures by the end of 2027 of which a positive contribution will be already realized in 2026.

To implement Horizon, Evotec expects total cash restructuring charges of approximately €100 million over the 2026–2028 period. There are also expected to be non-cash components related to asset impairments.

Evotec enters 2026 with annualized savings of approximately €60 million realized in 2025, fully embedded in its structurally lower operating cost and driven by improved capital discipline and a progressively more technology-driven revenue mix and base. These structural cost reductions, combined with improved utilization and a shift toward higher-margin technology and platform-based activities, are expected to enhance operating leverage and support sustained margin expansion from 2027 onward.

For full-year 2026, Evotec expects:

• Group revenues of approximately €700-780 million (€730-810 million CER)
• Adjusted Group EBITDA of approximately €0-40 million (€10-50 million CER)

Medium-Term Framework 2026–2030

Evotec is providing a new medium-term framework for 2026-2030 to consider the timing and impact of Horizon while maintaining its growth ambition. The framework reflects a phased trajectory.

• Group revenues are expected to grow to > €1 billion (8-12 % CAGR)

• Adjusted EBITDA margin is expected to reach 20% by 2028 and exceed that level by 2030

The framework reflects:

• Anticipated recovery of the early drug discovery and development market
• Cost reductions from Horizon with positive contributions beginning in 2026
• Continued shift toward higher-margin, technology-enabled, capital-efficient revenue streams
• Continued CAPEX-lighter approach to below 10 % of revenues
• Operating leverage as growth resumes following the 2026 transition year

This phased approach defines a clear trajectory from operational reset, through transition, to sustainable margin expansion and scalable growth by 2030. Further details on the medium-term framework will be provided during the final fourth quarter and full-year 2025 reporting on April 8, 2026.

Webcast Details

Evotec will host a webcast and conference call today at 3 p.m. CET / 2 p.m. GMT / 10 a.m. EDT.

To join the audio webcast and to access the presentation slides, please register via this link.

The on-demand replay of the webcast will be available under the same link after the event and on
our website.

Conference Call Details

To join the conference call, please pre-register via this link. You will receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.
A simultaneous slide presentation for participants dialing in via phone is available under this link.

About Evotec SE

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Investor Relations and Media Contact

Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com

Dermapharm Holding SE records decline in consolidated revenue, adjusted consolidated EBITDA improves

• In 2025, consolidated revenue decreases to EUR 1,165.0 million (-1.3%) following phase-out of low-margin products in “Parallel import business” segment
• Adjusted EBITDA increases by 2.9% to EUR 324.8 million; adjusted EBITDA margin at 27.9% (up 1.2 percentage points year on year)
• Unadjusted EBITDA rises by 2.8% to EUR 317.6 million, margin improves by 1.1 percentage points to 27.3%
• Earnings and margin development remains heavily dependent on structural measures

Grünwald, 10 March 2026 – Dermapharm Holding SE (“Dermapharm”), an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today published its unaudited preliminary consolidated figures (IFRS) for the 2025 financial year.

Consolidated revenue decreased to EUR 1,165.0 million in the reporting period (previous year: EUR 1,180.8 million). The 1.3% decline was due primarily to portfolio adjustments in the Parallel import business in the wake of the systematic phase-out of low-margin products. The organic growth in the “Branded pharmaceuticals” segment did not fully offset this decline.

Adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose by 2.9% to EUR 324.8 million (previous year: EUR 315.6 million), with the adjusted EBITDA margin amounting to 27.9% (previous year: 26.7%). Prior to adjustment, EBITDA increased by 2.8% to EUR 317.6 million (previous year: EUR 308.9 million). The EBITDA margin thus improved from 26.2% in the previous year to 27.3%.

“In 2025, we once again increased our earnings year on year. The systematic focus of our portfolio and the robust development of our core segments underscore the stability and profitability of our Company,” said Dr Hans-Georg Feldmeier, CEO of Dermapharm Holding SE.
 

Branded pharmaceuticals

The segment recorded growth in revenue as well as EBITDA. Organic growth remains solid on the back of a broadly diversified product portfolio. The acquisition of the Austrian pharmaceuticals company F. Trenka expands the Company’s international footprint in the MENA region.

Other healthcare products

The segment’s revenue trend in the reporting year remained on par with the prior-year level. Growth at Euromed and Anton Hübner did not fully offset the decline at Arkopharma. Currency-related effects resulting from the depreciation of the US dollar also weighed on earnings.

Parallel import business

In financial year 2025, Dermapharm continued to restructure its product portfolio with the aim of increasing its focus on high-margin products. Lucrative but low-margin products were gradually phased out. This restructuring led to a significant decline in revenue and earnings.

IFRS figures for 2025 and the previous year

 * 2025 EBITDA was adjusted for non-recurring items amounting to EUR 7.2 million.
   2024 EBITDA was adjusted for non-recurring items amounting to EUR 6.7 million.

Company profile:

Dermapharm – Pharmaceutical Excellence “Made in Europe”

Dermapharm is an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products. Founded in 1991, the Company is based in Grünwald near Munich. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations, including in Germany, the rest of Europe and the United States.

In the “Branded pharmaceuticals” segment, Dermapharm has more than 1,400 marketing authorisations with more than 400 active pharmaceutical ingredients. Dermapharm’s portfolio of pharmaceuticals is tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany. The Company’s integrated business model extends from in-house product development and production through quality management and logistics to the distribution of branded pharmaceuticals by a trained pharmaceutical sales force.

Dermapharm bundles food supplements, herbal pharmaceuticals, cosmetics, medical devices, herbal extracts and medicinal cannabis in its “Other healthcare products” segment. In this segment, Dermapharm can tap the expertise of Arkopharma, the market leader for phytotherapeutic food supplements in France, and the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, foodstuffs and cosmetics industries.

Dermapharm also operates the “Parallel import business” segment under the axicorp brand. axicorp imports originator pharmaceuticals from other EU Member States and resells them to pharmaceuticals wholesalers and pharmacies in Germany. This enables axicorp to benefit from the different pricing structures in the individual EU member states. Based on revenue, axicorp is currently the seventh largest parallel importer in Germany.

With a consistent R&D strategy and numerous successful product and company acquisitions and by stepping up its internationalisation efforts, the Group is continuously optimising its business activities and seeks external growth opportunities in addition to organic growth.

Contact

Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 – 64186-233
E-mail: ir@dermapharm.com

Ad hoc announcement – Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 

Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital

• Heidelberg Pharma is eligible to receive USD 20 million upfront funded by Soleus Capital, subject to closing conditions
• USD 25 million to be funded by Soleus Capital upon FDA approval of Telix Pharmaceuticals’ imaging diagnostic agent TLX250-Px; HCRx payment upon approval still in place

Ladenburg, Germany, 7 March 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced an additional amendment to its existing royalty purchase agreement with HealthCare Royalty (HCRx) and the participation of Soleus Capital Management, L.P. (Soleus Capital), a US-based life sciences investment firm, on behalf of its Soleus Capital Credit Opportunities Fund I, L.P. (and its affiliated funds). The amended agreement covers the partial monetization of Heidelberg Pharma’s future royalties on the worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent TLX250-Px. In conjunction with the amendment, Heidelberg Pharma is eligible to receive USD 20 million from Soleus Capital, subject to customary closing conditions. Another payment of USD 25 million will become due upon FDA approval of TLX250-Px.

In March 2024, Heidelberg Pharma entered into an agreement with HCRx for the sale of royalties on TLX250-Px up to a defined cap, which agreement was subsequently amended in March 2025. As part of the current amendment, Heidelberg has agreed to an increased cap on total payments alongside certain other contractual changes. The participation of Soleus Capital has no impact on the payments from HCRx.

Key terms of the agreement between Heidelberg Pharma, HCRx and Soleus Capital are:

• Heidelberg Pharma will receive a USD 20 million payment under the amended agreement, funded by Soleus Capital, subject to customary closing conditions expected to be fulfilled shortly.
• Heidelberg Pharma will receive another USD 25 million payment funded by Soleus Capital upon FDA approval of TLX250-Px. The calculation of the FDA approval milestone payment from HCRx under the existing agreement remains unchanged under this amendment.
• Once the maximum cumulative amount of royalties sold is reached under the amended agreement, a high single-digit royalty tail percentage amount will be due under the amended agreement and remaining royalty payments will revert to Heidelberg Pharma.
• Based on current planning, available funds and the today signed agreement, the Company’s financing will be secured until mid-2027.

Berlin, 6 March 2026. The Executive Board of Eckert & Ziegler (ISIN DE0005659700, TecDAX) intends to propose to the Annual General Meeting a dividend of € 0.22 per share for the 2025 financial year (previous year, split adjusted: € 0.17). The Supervisory Board will decide on the proposal for the appropriation of profits at its regular meeting on the company’s annual financial statements. The dividend payment is subject to the resolution of the Annual General Meeting.

The detailed annual financial statements for 2025 will be published on March 26, 2026.

For enquiries please contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

Press release

Appointment of Falk Neukirch as Chief Financial Officer to expire on April 30, 2026

Berlin, March 6, 2026 – The Supervisory Board of Medios AG announces that the appointment of Falk Neukirch as Chief Financial Officer (CFO) of Medios AG will not be extended beyond the end of his current term in April 2026 at his own request.

Following the successful repositioning and international expansion of the Medios Group, Falk Neukirch has decided to pursue new professional opportunities. This also provides the opportunity to realign the Group’s leadership structure under the leadership of the new Chief Executive Officer (CEO), Thomas Meier.

Since the beginning of his tenure in October 2021, which was extended in May 2023 until April 2026, Mr. Neukirch has played a key role in shaping and advancing the development of the Medios Group. In particular, he elevated systems, processes and structures in the areas of finance and controlling to a new level, significantly enhancing transparency and steering capability across the Group. This included, among other achievements, the successful implementation of a new ERP system, the rollout of which commenced in January 2026.

In addition to operational improvements, Mr. Neukirch made a substantial contribution to the successful execution of several significant acquisitions and the swift integration of the acquired entities into the Medios Group’s finance organization. This particularly included the acquisition and integration of the CEBAN Group in 2024, during which more than 50 entities were successfully integrated into the finance function within a very short period of time. In this context, under Mr. Neukirch’s leadership, long-term bank financing in the amount of €225 million was secured.

Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG: “Falk Neukirch has played a decisive role in shaping Medios’ development since 2021 and has made important contributions to the further advancement of our organization. With strong financial expertise and strong commitment, he has sustainably strengthened the finance function and made a significant contribution to the transparency and stability of the Group. He has also provided decisive support to the Company’s positive development through his involvement in strategically important projects and acquisitions.”

The Supervisory Board expressly thanks Mr. Neukirch for the trusting and constructive cooperation, his dedication and his valuable contribution to the positive development of the Medios Group. During a key phase of transformation, Mr. Neukirch advanced the Group with prudence and a high level of professional expertise.

To ensure a smooth handover of responsibilities, Mr. Neukirch will remain available to the Company in an advisory capacity on a transitional basis.

Important events for Medios AG in the 2026 financial year:

——————-

About Medios AG

Medios is a leading provider of specialty pharmaceuticals in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios focuses on future-oriented individual medicine to enable all people to receive the most innovative therapies together with pharmacies, specialist practices, and pharmaceutical companies.

Medios AG is Germany’s first listed specialty pharmaceutical company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) and are listed in the SDAX selection index.

www.medios.group

More information on the topic of individual medicine: https://app.medios.group/individualmedizin

Contact

Claudia Nickolaus

Head of Investor & Public Relations, ESG Communications

Medios AG

Heidestraße 9 | 10557 Berlin

T +49 30 232 566 800

ir@medios.group

www.medios.group

Disclaimer

This release contains forward-looking statements that are subject to certain risks and uncertainties. Future results may differ materially from those currently anticipated due to various risk factors and uncertainties, such as changes in business, economic and competitive conditions, exchange rate fluctuations, uncertainties regarding litigation or investigations, and the availability of funds. Medios AG assumes no responsibility to update the forward-looking statements contained in this release.

Cellbox Solutions closes first tranche of Series A financing and appoints new CBO/CFO to accelerate international growth

• Companisto leads ~EUR 3.5 million investment round to scale Cellbox’s™ global warm-chain logistics platform
• Dr. Bernd Muehlenweg joins as Chief Business Officer and Chief Financial Officer to drive international expansion and service portfolio growth

Cologne, Germany, March 5, 2026 – Cellbox Solutions, a warm-chain logistics technology company enabling the global transport of living cells under controlled physiological conditions, today announced the first closing of its Series A financing round, raising approximately EUR 3.5 million. The round is led by the digital business angel network Companisto, together with existing investors, including NRW.BANK. The new capital will be used to expand international production and sales activities and to unlock additional application areas, particularly in cell and gene therapy as well as in vitro fertilization (IVF). In addition, the management team is strategically strengthened with the appointment of Dr. Bernd Muehlenweg to further drive growth and scalability. This is the first closing of a Series A financing round which remains open for other tranches until May 2026.

Cellbox™ develops portable CO₂ incubators for the safe transport of living cell samples. Its patented warm-chain technology enables continuously controlled shipment conditions for up to 48 hours, preserving cell viability and functionality during transport. The systems are certified and compliant with IATA regulations for air transport. More than 300 devices are already in use worldwide by leading customers in the pharmaceutical and biotechnology industries, applied research institutions, and universities.

A key component of this next growth phase is the appointment of Dr. Bernd Muehlenweg as Chief Business Officer (CBO) and Chief Financial Officer (CFO) of Cellbox™. He joins the company full-time with more than 20 years of international experience in the life sciences industry. Most recently, Dr. Muehlenweg served as Senior Vice President and Global Head of Business Development, Cell Therapy at Evotec, where he led international commercial and strategic partnership activities in the advanced therapy space.

“Cellbox™ is setting a new benchmark in the transportation of living cells. By enabling safe, controlled, and reproducible transport under physiological conditions, we address a critical bottleneck in the life sciences industry. The investment round marks an important milestone in expanding our international footprint and establishing Cellbox™ as a global infrastructure standard for living cell shipment and warm-chain logistics. Our patented platform and strong regulatory positioning provide an excellent foundation for global scale-up across multiple life sciences applications, including the rapidly growing field of cell and gene therapies. I look forward to further strengthening our commercial operations, expanding our service portfolio, and building the organizational structures required to support the next phase of international growth,” commented Dr. Bernd Muehlenweg, CBO & CFO of Cellbox Solutions GmbH.

“Cellbox™ addresses a structural gap in the life sciences value chain: the reliable transport of living cells at physiological conditions. As advanced therapies scale globally, logistics becomes a critical success factor. We view Cellbox™ not as an incremental product innovation, but as a scalable platform with the potential to redefine how sensitive biological materials are transported across research and clinical environments,” added Dr. Robin Ghosh, Investment Manager at Companisto.

Companisto will actively support Cellbox™ in its next growth phase. As a fully digitalized business angel network, Companisto contributes not only capital but also targeted strategic expertise to international scaling.

“Our vision is to redefine how living cells are transported globally. With the continued support of our investors and the strengthening of our leadership team with a highly experienced executive, we are building the foundation for long-term international growth and expanding the reach of warm-chain logistics across clinical and research applications. We are convinced that reliable live-cell transport will become an essential component of the global life sciences value chain,” concluded Prof. Dr. Kathrin Adlkofer, Founder and CEO of Cellbox™.

In the long term, Cellbox™ aims to establish warm-chain logistics as the preferred global approach for transporting living cells, cell therapies, and sensitive biological materials, further advancing reliability and reproducibility across the life sciences sector.

About Cellbox Solutions GmbH

Founded in 2017, Cellbox Solutions GmbH is a Germany-based warm-chain logistics technology company providing innovative solutions for the global healthcare and life sciences industries to transport sensitive biological materials and therapeutics that cannot be frozen and require controlled physiological conditions. The company’s portable CO₂ incubator platform, Cellbox™, creates a regulated environment for the transport of living cells, organoids, tissues, and other advanced biological materials. Temperature and CO₂ levels are individually adjustable to ensure reproducible incubation conditions throughout shipment. Cellbox™ systems are deployed globally and support research, clinical, and advanced therapy applications. For more information, please visit www.cellbox-solutions.com or follow Cellbox Solutions on LinkedIn.

About Companisto

Companisto is a digital business angel network that enables private and institutional investors to participate in venture capital investments in innovative growth companies. Since its founding, Companisto has successfully financed numerous startups and growth-stage companies and actively supports them with capital, expertise, and a strong investor community.

Contacts

Prof. Dr. Kathrin Adlkofer, CEO Cellbox™
office@cellbox-solutions.com
Sophie Schultheiss, Companisto
presse@companisto.com
+49 (0)30 208 484 957

Media inquiries

MC Services AG

Dr. Cora Kaiser
cellbox@mc-services.eu
+49-(0)89 210 228 60

Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014

Formycon AG publishes preliminary figures for the 2025 fiscal year

• Strong increase in Group revenues in the fourth quarter, but full-year revenues still expected to remain below guidance
• Group EBITDA expected to be at the upper end of the expected range
• Adjusted EBITDA as well as working capital expected to be improved versus guidance

Planegg-Martinsried, Germany, March 4, 2026 – Based on preliminary and unaudited figures, Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) (“Company” or “Formycon“) expects Group revenues for the 2025 fiscal year to amount to approximately € 45 million. Despite a strong increase in the fourth quarter, total revenues are below the previously communicated forecast range of € 55 million to € 65 million. This is partly due to longer negotiations to conclude further commercialization and development partnerships, for example for the Keytruda^®1 biosimilar candidate FYB206, in order to optimize their financial terms. In addition, recognition of milestone events anticipated for Q4 shifted to the first quarter of 2026. Furthermore, while revenue contributions from FYB202 increased significantly in Q4, the product is still in the early phase of commercialization and did not ramp up as quickly as expected.

In this context, based on the results of the impairment test available to date, the company expects that the valuation model and balance sheet measurement for FYB202 will need to be reviewed and adjusted to reflect this slower ramp up. According to Formycon’s commercialization partners, market uptake of FYB202 is developing positively. However, despite encouraging political signals, the pharmacy benefit market (PBM) in the U.S. is still opening only gradually. Based on preliminary calculations, the company expects an extraordinary, non-cash and non-EBITDA-relevant impairment requirement in the low to mid double-digit million range.

The Group’s earnings before interest, taxes, depreciation and amortization (Group EBITDA) for the 2025 fiscal year is expected to amount to approximately € -12 million, at the upper end of the forecast range of € -20 million to € -10 million. Adjusted consolidated earnings before depreciation and amortization (Group adjusted EBITDA), which also shows the total income of the FYB201 ranibizumab biosimilar, is expected to be approximately € -7 million, which is above the most recently communicated forecast range of € -20 million to € -10 million. The significantly better-than-expected at-equity result (approx. € 5 million) from the 50% stake in Bioeq AG mainly benefited from the upfront payment from the partnership of FYB201/Nufymco^®2.

The Company expects a further improvement in working capital to approximately € 73 million, which is significantly above guidance. Due to the € 70 million corporate bond placed in July 2025, Formycon had already raised its forecast for this key figure from the original € 25 million to € 35 million to € 55 million to € 65 million upon publication of its half-year results for 2025. Significant upfront payments in connection with initial partnerships for the Keytruda^® biosimilar candidate FYB206 in 2025, strict cost management and efficiency improvements contributed to a further increase.

The final financial figures and further information on the 2025 financial year as well as the outlook for 2026 will be published on 26 March 2026 with the annual report for the 2025 financial year on the website under Publications – Formycon AG .

————-

1. Keytruda® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ/USA
2. Nufymco® is a registered trademark of Formycon AG

Contact
Sabrina Müller
Director Investor Relations & Corp. Communications
Formycon AG,
Fraunhoferstraße 15,
82152 Planegg/Martinsried,
Germany

Phone +49 (0) 89 – 86 46 67 149 | Fax + 49 (0) 89 – 86 46 67 110
ir@formycon.com // www.formycon.com

Disclaimer

Certain statements contained in this release may constitute “forward-looking statements” that involve a number of risks and uncertainties. Forward-looking statements can generally be identified by the use of the words “may”, “will”, “should”, “plan”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “project”, or “target” or the negative of these words or other variations of these words or comparable terminology. Forward-looking statements are based on assumptions, forecasts, estimates, predictions, opinions or plans that are inherently subject to significant risks, uncertainties and uncertainties that are subject to change. The Company makes no representation and does not make any representation that any forward-looking statement will be achieved or prove to be accurate. Actual future business, financial condition and results of operations and prospects may differ materially from those projected or projected in the forward-looking statements. Subject to applicable legal requirements, neither the Company nor any other person intends to update, review, revise or conform to actual events or developments any forward-looking statements contained in this announcement, whether as a result of the availability of new information, new developments in the future or otherwise, nor does they assume any such obligation.